Evogene Ltd. and its subsidiaries, operate as a biotechnology company. The company focuses on developing products for life science markets through the use of a computational predictive biology platform. The company has developed a proprietary predictive computational biology platform, leveraging scientific understanding and computational technologies to harness biological ‘Big Data’ to develop products for life science markets, such as improved seed traits, ag-chemical products and ag-biological products. The company primarily engages in the development of seed traits for improved yield and abiotic stress tolerance, plant disease and insect control, herbicides, insecticides, bio-stimulants and bio-pesticides. The product candidates the company develops focuses mainly on essential crops, including corn, soybean, wheat, rice, and cotton. In addition, the company operates a seed business under its wholly-owned subsidiary, Evofuel Ltd. (Evofuel), which focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company’s subsidiary, Biomica Ltd. (Biomica) focuses on the discovery and development of human microbiome-based therapeutics. The company also owns Evogene Inc. (Evogene). Segments The company operates through Evogene, Evofuel and Biomica segments. Evogene This segment includes the activities preformed under the company’s Crop Enhancement (CE) and Crop Protection (CP) divisions, including seed traits, ag-chemicals and ag-biological activities. CE Division The CE division develops products to increase crop performance and productivity with its main focus on enhancing yield, tolerance to abiotic stresses, such as drought, heat and salinity and fertilizer use efficiency in key commercial crops, or target crops, such as corn, soy, wheat, rice and cotton. The CE division focuses on the development of two types of products: CE seed traits, which are seed traits having improved yield, abiotic stress tolerance and fertilizer use efficiency, through biotechnology and advanced breeding methods; and ag-biologicals, focusing on microbial-based bio-stimulants and bio-pesticides, which are microbial-based products to serve as externally-applied treatments for improving yield, abiotic and biotic stress tolerance. In the CE division, the company generates revenues from research and development payments for discovery and optimization activities under the CE seed traits activity. CE Seed Traits The company’s CE seed traits activity focuses on seed traits that have a direct impact on crop productivity, through biotechnology and advanced breeding. In the field of CE seed traits, the company collaborates with seed companies, including Biogemma and Monsanto Company (Monsanto). Typically, under these collaborations the company discovers and validates candidate trait-improving genes and other genetic elements, and subsequently its collaborators, under license from it, test and further develop these discoveries in their product development pipelines with the goal of introducing them into commercial crop seeds. Its collaborations cover a portfolio of 4 key product programs, tailored to address specific market needs across various crops and traits. Ag-Biologicals The company focuses on the development of microbial based yield improvement and pest control products. In 2015, the company initiated its ag-biologicals activity for developing ag-biological products. Ag-biologicals are externally-applied products from biological sources, such as microbial (micro-organisms) and naturally derived biochemistries, designed to improve crop productivity. The company’s ag-biologicals operations are mainly focused on bio-stimulants with initial activity in the area of bio-pesticides. The company’s activity focuses on discovery and development of next generation microbial based ag-biologicals, converging the plant and microbial worlds to decipher plant-microbiome-pest complex interaction and cross talk. The company’s technological platform includes a proprietary computational predictive biology platform, validation techniques, formulation and fermentation technologies and othe
evogene ltd (EVGN:Tel Aviv)
13 Gad Feinstein Street
PO Box 2100
Phone: 972 8 931 1900
Fax: 972 8 946 6724www.evogene.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for EVGN.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact EVOGENE LTD, please visit www.evogene.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.